Literature DB >> 25726051

Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation.

Siva P Raman1, Yifei Chen1, Elliot K Fishman2.   

Abstract

Pancreatic cancer is an extraordinarily morbid malignancy with a poor prognosis. As a result, it is imperative that imaging examinations correctly identify tumors when they are relatively small and potentially still resectable, as well as accurately stage tumors to determine which patients should undergo definitive surgery. Multidetector computed tomography (MDCT) has been established as the most important modality for both initial diagnosis and staging, although positron emission tomography (PET) and magnetic resonance imaging (MRI) both play important ancillary roles. This review discusses how these three modalities play complementary roles in tumor diagnosis and staging.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25726051     DOI: 10.1053/j.seminoncol.2014.12.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

Review 2.  Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

3.  Usefulness of endoscopic ultrasound-guided fine needle aspiration for lymphadenopathy.

Authors:  Yuki Tanisaka; Shomei Ryozawa; Masanori Kobayashi; Maiko Harada; Tsutomu Kobatake; Kumiko Omiya; Hirotoshi Iwano; Shin Arai; Kouichi Nonaka; Yumi Mashimo
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.